$1.09
0.00% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US75989R1077
Symbol
RNXT
Sector
Industry

RenovoRx Inc Stock News

Neutral
GlobeNewsWire
one day ago
Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrollment As of September 30, 2024, the Company had $9.6 million in Cash, Sufficient to Fund Op...
Neutral
GlobeNewsWire
about 2 months ago
Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath
Neutral
GlobeNewsWire
about 2 months ago
Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months
Neutral
GlobeNewsWire
3 months ago
LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the ...
Neutral
GlobeNewsWire
3 months ago
Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout United States participating in the study LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc.
Neutral
GlobeNewsWire
4 months ago
Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal Publication of data relating to RenovoRx's targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the Summer 2024 issue of a prestigious journal
Neutral
GlobeNewsWire
5 months ago
Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer
Neutral
GlobeNewsWire
5 months ago
New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today